and tamoxifen was administered to induce Cre-mediated TdTomato expression. Endothelial specificity was validated by co-staining the heart sections with an antibody against the endothelial cell marker VEGFR2 (AF644, R&D Systems; 1:50).
Adeno-associated viral vectors
The recombinant adeno-associated viral vectors (AAV, serotype 9) encoding mVEGFB186, mPlGF, mVEGF164 and Scrambled control vector were constructed and generated as described previously 7 . All the vectors contained CAG-promoter. The mice were injected with 2 x 10 11 AAV9
particles intraperitoneally (i.p.) and analyzed 2-6 weeks later. In addition, we generated recombinant AAV-mErbB4ECD-mFc, which encodes the extracellular domain of mouse ErbB4
receptor fused with mouse Fc.
Blocking VEGFR2 by monoclonal antibody DC101
To block VEGF/VEGFR2 signaling, eight weeks old C57BL/6J wild type mice were injected with AAV-Ctrl, AAV-mVEGFB186 or AAV-mPlGF and treated with DC101 mAb (30 µg/g, BioXcell)
every 3-4 days. In the prevention study, DC101 injections were started at the same time as the AAVs were injected and the mice were terminated after two weeks. In the treatment study, mice were first injected with AAVs and the two-week antibody treatment was started two weeks later, when cardiac hypertrophy was established.
Effect of AAV9-mErbB4ECD on VEGFB-induced cardiac hypertrophy
To study the effects of ErbB signaling inhibition on VEGFB-induced cardiac hypertrophy, recombinant AAV9-mErbB4ECD or AAV9-Ctrl was injected i.p. together with AAV9-mVEGFB186 i.p to wild type C57BL/6J mice. The AAV viral particles were injected in the following four combinations (the respective viral particle concentrations are mentioned within the 4 VEGF (50ng/ml) for 1, 3 or 6 hours. Culture media were collected and subjected to ELISA analysis for neuregulin1-b1 protein.
To silence Flt1 (VEGFR1), Mouse Brain endothelial cells (bEND.3, ATCC) were cultured and maintained in DMEM (Corning, #10-014-CVR) supplemented with 10% FBS, penicillin (100 U/mL) and streptomycin (100 µg/mL). The lentiviral vectors encoding two different clones of mouse Flt1 shRNA constructs (TRCN0000009606 and TRCN0000009608 obtained from FuGU core facility, University of Helsinki) were used to transfect bEND cells for 24 hours and the cells were then treated with puromycin (2 µg/mL) for 48 hours to select Flt1 silenced cells. After that the cells were harvested and used for further molecular analyses.
ELISA
ELISA was used to quantify protein levels of mouse VEGFR1 (DuoSet DY471, RnD Systems), mouse VEGFR2 (DuoSet DY493, RnD Systems), mouse PlGF (DY465, RnD Systems) and mouse VEGFB186 (in house ELISA based on RnD Systems antibodies AF590 and BAF767 and recombinant mVEGFB186 767-VE). Neuregulin-1 was determined from conditioned media using Nrg-1 Elisa Kit (DuoSet DY377, RnD Systems).
VEGFR1 recombination PCR
To verify the recombination of VEGFR1, genomic DNA was isolated from mouse ear skin and heart. The forward and reverse primer sequences 5'-AGAAGATGCGTGGGCGTTAG-3 were used to amplify the region containing the loxP sites in the construct. The PCR product was resolved in 1.5% agarose gel electrophoresis and the recombined and non-recombined amplicons were detected at ≈ 400bp and ≈ 2500bp, respectively.
Real time quantitative PCR
The apex portion of the adult mouse heart was homogenized in 700µl of TRIsure™ reagent (Bioline, USA) using the bead-based tissue homogenizer PowerLyzer®24 (MO BIO Laboratories, USA). Total RNA was purified and isolated using NucleoSpin RNA II Kit (Macherey-Nagel)
according to the manufacturer's protocol. RNA was reverse transcribed into cDNA with iScript cDNA synthesis Kit (Bio-Rad) and gene expression was analyzed using SYBR green gene or 
Whole-genome microarray
The quality of RNA was determined with Bioanalyzer (Agilent Technologies) and analysed on genome-wide Illumina Mouse WG-6 v2 Expression BeadChips (Illumina). Illumina's GenomeStudio software was used for initial data analysis and quality control and the further data analysis was performed with the Chipster software (www.chipster.csc.fi) 8 . After quantile normalization, statistically significant differences in expression of individual genes between the groups were tested using Empirical Bayes statistics and the Benjamini-Hochberg algorithm controlling false discovery rate (FDR). Adjusted FDR values of P<0.05 were considered significant.
The microarray data have been submitted to the GEO database, under the series accession number GSE110532. Further, the UniProt accession numbers of the up and down regulated genes were retrieved and imported into the MetazSecKB proteome knowledgebase to characterize the subcellular localisation, molecular function and secretome properties of the gene encoding proteins 9 .
Immunofluorescent staining
10 µm thick transverse heart sections were fixed with acetone, blocked with Donkey Immuno Mix (DIM) and incubated with the respective primary antibodies (Supplemental Table 3 10 .
Western blotting
Mid-portion of the heart was homogenized in RIPA lysis buffer containing aprotinin, 1mg/ml Leupeptin, 1M PMSF, 1M NaF, 0.1M Na3VO4, 0.5% Triton X-100 (v/v) and 0.5% NP-40 (v/v) in PBS pH 7.4. The total protein concentration was determined using BCA protein assay kit (Pierce, Thermo Scientific). Equal amounts of total protein were resolved in 7.5% Mini-PROTEAN TGX Precast gels (Bio-Rad) and transferred to PVDF membrane (immobilon-P, Millipore). The blots were blocked with 5% BSA (wt/vol) in TBS containing 0.1% Tween 20 and incubated overnight at 4°C with primary antibodies (Supplemental Table 3 
Vascular Permeability by Miles assay
The Pdgfb-CreERT2;Flt1 lox/lox mice were treated with tamoxifen and AAVs encoding VEGFB186
(2 x 10 11 viral particles) and VEGFA164 (0.4 x 10 11 viral particles) were injected intraperitoneally and allowed to express for two weeks and for four days, respectively. To analyse the vascular permeablity by Miles assay, the mice were anesthetized with ketamine/xylazine and 100µl of 3%
Evans Blue dye was dissolved in PBS and injected retro-orbitally under anesthesia. The dye was allowed to circulate for one hour and the mice were transcardially perfused with PBS. The heart, lungs, skeletal muscle (tibialis anterior) and kidney were harvested, weighed and Evans blue dye was extracted by incubating the tissues in 500µl of deionized formamide for overnight at 55°C. The optical density of the Evans blue was measured at 610 nm 11 . The data is presented as ng of Evans
Blue extravasated per mg of tissue dry weight 12 .
Echocardiography
To analyse cardiac function and dimensions of the left ventricular chamber, thoracic cavity hair was removed and mice were anesthetized by inhalation with 2% isoflurane mixed with 0.5L/min 100% oxygen (Vevo Compact Dual Anesthesia System). The mice were placed on the heating stage (Vevo Imaging Station) in supine position, 1-1.5% isoflurane mixed with 0.5L/min 100% oxygen were supplied continuously via the nose cone to maintain the mice under sedation. Electrode gel was applied to the paws connected to ECG electrodes. Prewarmed ultrasound gel was applied on the thoracic cavity, heart rate between 430 -450 beats per minute were maintained and twodimensional (2D) ECG images were acquired using MS550D 22-50 MHz linear array solid-state transducer (Vevo 2100 Ultrasound, FUJIFILM VisualSonics). The ECG images in B-mode were used to confirm the anatomic boundaries of the ventricular chambers and M-mode along the parasternal short axis view using modified Simpson's method were used to measure left ventricular internal diameter, left ventricular posterior wall thickness, interventricular septum thickness at endsystole and end-diastole. These parameters were used to calculate left ventricular mass, volume, ejection fraction and fractional shortening (Vevo Vasc Analysis software). The data were reported as mean ± SEM.
Maximal exercise test
The maximal endurance capacity was measured on a treadmill (LE 8710, Bioseb) by incremental maximal running test. For adaptation, mice were familiarized on the treadmill for two days for 15 min at the speed of 15 m/s. In the maximal exercise test the speed was increased from 15 m/s by 5 m/s two times in 5 min interval (for total of 15 min) and then the speed was increased by 2 m/s every 2 min until exhaustion. Total running distance (m) and time (min) were recorded.
Blood Pressure measurement
Tail-cuff method (CODA Blood Pressure System, Kent Scientific) was used to measure blood pressure (BP) from the tail blood volume. Prior to the actual measurements the experimental mice were trained and acclimatized to the CODA mouse holder, nose cone and tail cuff (Occlusion and Volume Pressure Recording (VPR) cuff) for 10min and repeated for 3 consequetive days. On the day of actual experiment, the mice were transferred to the mouse holder, nose cone was adjusted to prevent the mice from moving, occlusion cuff was fixed to the proximal end of the tail followed by 
